SLC25A5 and breast carcinoma: Even by itself, ANT2 shRNA has an anticancer effect in breast cancer cell lines, acting through a mechanism involving the induction of p53 activity, JNK activation, DNMT1 expression, DR4/DR5 up-regulation, and DcR2 down-regulation, thereby making the cells susceptible to TRAIL-induced apoptosis.